M ammalian SWI/SNF (mSWI/SNF) complexes are ATPdependent chromatin remodellers that modulate genomic architecture and DNA accessibility, thus enabling timely and appropriate control of gene expression [1][2][3][4][5][6][7][8][9][10][11] . They are combinatorially assembled from the products of 29 genes into three final-form complexes: canonical BAF (cBAF), polybromo-associated BAF complexes (PBAF) and a non-canonical BAF (ncBAF), with specific subunits specifying distinct complexes, such as PBRM1, ARID2 and BRD7 in PBAF, ARID1A/ARID1B and DPF2 in cBAF and GLTSCR1/ GLTSCR1L and BRD9 in ncBAF complexes [12][13][14][15] . The specific genome-wide targeting and biochemical functions of these distinct complexes remain poorly understood, owing in part to limitations in understanding their full subunit composition, combinatorial parameters, assembly pathways and the paucity of robust strategies to map the relative localization of each complex on chromatin.
While the majority of mSWI/SNF gene mutations result in loss-of-function phenotypes, the SS18-SSX fusion hallmark to synovial sarcoma results in de novo, gain-of-function targeting of BAF complexes, which activates the unique synovial sarcoma gene expression signature 23 . The incorporation of the SS18-SSX oncoprotein into BAF complexes results in protein-level destabilization of SMARCB1 (a feature shared with MRT), but this event is secondary and not required for the maintenance of synovial sarcoma gene expression or proliferation 23 . Finally, genetic perturbation screens in cell lines bearing mutations in mSWI/SNF subunits that are part of paralog families (such as SMARCA4 and ARID1A) have unveiled synthetic lethal dependencies on residual complexes assembled with their rarely mutated partner paralogs (such as SMARCA2 and ARID1B) 24, 25 . Collectively, these findings highlight subunit-and paralog-specific biological roles, such as those demonstrated in the context of development 4, [8] [9] [10] .
Defining the functional differences among the diverse array of complexes within the mSWI/SNF family represents a major goal for the field at large. In this study, we used biochemical and bioinformatic approaches to map mSWI/SNF complexes on chromatin, which revealed an unexpected, complex-specific localization of ncBAF complexes to CTCF and promoter-proximal sites. We find that cancers driven by core cBAF subunit perturbations, such as synovial sarcoma and MRTs, are uniquely dependent on ncBAF function. We further demonstrate that perturbation of Articles NATuRe Cell BIology ncBAF complexes is, unexpectedly, mechanistically distinct from perturbation of synovial sarcoma disease-driver SS18-SSX and that in both synovial sarcoma and MRT settings, ncBAF plays critical roles in maintaining gene expression at retained mSWI/ SNF sites.
Results
Distinct function and genome-wide localization across mSWI/ SNF complex families. Genes that encode proteins involved in similar biological pathways or protein complexes often exhibit coordinated fitness variation in genetic perturbation screens, such correlations between mSWI/SNF genes from combined genome-scale RNAi-and CRISPR-Cas9-based genetic perturbation screens (Project Achilles). b, SDS-PAGE and silver staining performed on purified complexes using the indicated HA-tagged subunits expressed in HEK-293T cells. The purifications were performed in n = 3 biologically independent experiments for each bait. c, Protein abundance as assayed by proteomic mass spectrometry performed on mSWI/SNF complexes purified from HEK-293T cells expressing the indicated HA-tagged mSWI/SNF subunits. d, Immunoprecipitation of endogenous SMARCA4 (pan-mSWI/SNF complex component), ARID1A (cBAF-specific), BRD7 (PBAF-specific), and BRD9 (ncBAF-specific) subunits in HEK-293T nuclear extracts followed by immunoblotting for select subunits (n = 2 biologically independent experiments). See also Supplementary Fig. 7a . e, Separation of HEK-293T nuclear extracts through 10-30% glycerol gradient density sedimentation followed by immunoblotting for selected mSWI/ SNF subunits (n = 3 biologically independent experiments). See also Supplementary Fig. 7b . f, Schematic depicting biochemical subunit compositions of mammalian ncBAF, cBAF and PBAF complexes. The subunits in blue, red, and green represent BAF-, PBAF-and BRD9/GLTSCR1-specific complexes, respectively. Shared subunits are shown in grey.
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NATuRe Cell BIology as those performed across hundreds of human cancer cell lines [26] [27] [28] [29] . Specifically, we have previously established that mSWI/SNF complex genes cluster into three functional modules: cBAF, PBAF and ncBAF 12 . Similar analyses performed on a combined shRNA-and CRISPR-Cas9-based dataset (Project Achilles, Broad Institute) 26, 27, 30 , as well as the Project DRIVE (Novartis) dataset 29 , further suggest that cBAF, PBAF and ncBAF on average represent functionally distinct entities, thus providing motivation to define their underlying features ( Fig.  1a and Supplementary Fig. 1a ). Importantly, in agreement with these functional distinctions, biochemical studies resolved complexes of distinct size and componentry, as demonstrated by complex purifications, mass-spectrometry and density sedimentation ( Fig. 1b-f , Supplementary Fig. 1b-e and Supplementary Table 1 ). Specifically, we found that ncBAF complexes uniquely lack core, evolutionarily conserved subunits such as SMARCB1 and SMARCE1, incorporate selective paralogs (that is, SMARCC1 but not SMARCC2 and SMARCD1 but not SMARCD2 or SMARCD3) and contain a set of complex-specific subunits that are not shared by cBAF or PBAF, the GLTSCR1/1L paralogs and BRD9.
To begin characterizing these distinct assemblies and determining whether differential targeting on chromatin may in part underlie their differences, we performed comprehensive genomewide mapping of cBAF, PBAF and ncBAF complexes by performing chromatin immunoprecipitation-sequencing (ChIP-seq) in a mSWI/SNF-intact cell line, EoL-1, using antibodies against pan-mSWI/SNF subunits (SMARCC1 and SMARCA4) and complexspecific subunits BRD9 and GLTSCR1 for ncBAF, DPF2 for cBAF and BRD7 for PBAF ( Supplementary Fig. 2a ). Consistent with biochemical studies, BRD7, DPF2, and BRD9 and GLTSCR1 peaks comprised subsets of all SMARCA4 ATPase subunit peaks and ChIP was performed on n = 2 independent samples for each. c, Localization of ncBAF, BAF and PBAF complexes at the VEGFA locus. Chromatin immunoprecipitation was performed on n = 2 independent samples for each. d, Heatmap of CentriMo log-adjusted P values for top motifs returned by MEME-ChIP analysis for each ChIP-seq experiment. Experiments were performed on n = 2 independent samples for each. P values were calculated using a binomial test. e, Proportion of peaks from ChIP-seq experiments using indicated antibodies that overlap the CTCF ChIP-seq peaks in MOLM-13 and EoL-1 cell lines. f, The proportion of cBAF-, PBAF-and ncBAF-specific peaks overlapping with specified chromatin features (see also Supplementary Fig. 2i ). g, Example tracks demonstrating differential enrichment of mSWI/SNF complex families across the AFTPH locus. ChIP was performed in n = 2 independent samples for each.
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NATuRe Cell BIology BRD9 and GLTSCR1 peaks significantly overlapped one another ( Fig. 2a and Supplementary Fig. 2b-d ). Hierarchical clustering performed on ChIP-seq read density over the merged set of peaks across all ChIPs identified distinct, complex-specific enrichment on chromatin ( Fig. 2b and Supplementary Fig. 2e ), such as ncBAF complexes over the promoter (green), PBAF complex occupancy into the gene body (red) and cBAF complexes at distal sites (blue) at the VEGFA locus ( Fig. 2c ). PBAF and ncBAF complexes exhibited a distinct promoter-proximal distribution in comparison to cBAF, which were substantially more localized to distal sites ( Supplementary Fig. 2f ). In addition, at transcription start sites (TSSs), PBAF complexes were more enriched over gene bodies relative to ncBAF complexes ( Fig. 2c and Supplementary Fig. 2g ). Motif analyses revealed a central enrichment of cBAF complexes over known transcription factor motifs, including FOS/JUN, AP-1, SPDEF and ETS (with PBAF complexes enriched at a subset of 
NATuRe Cell BIology these). However, ncBAF complexes specifically localized to CTCF sequence motifs, sites that are known to play important roles in the maintenance of DNA architecture [31] [32] [33] [34] (Fig. 2d ). We performed ChIP-seq for CTCF and found that ncBAF complexes strongly and selectively co-localized with CTCF across different cell lines ( Fig. 2e and Supplementary Fig. 2h ). Canonical BAF complexes were most enriched at active enhancers (H3K27ac and H3K4me1) and highly localized to primed sites (H3K4me1), suggesting roles for cBAF in enhancer regulation (Fig. 2f,g and Supplementary Fig. 2i-k) . In contrast, a greater proportion of PBAF complexes were localized to active promoters (H3K27ac and H3K4me3) among the three complexes, of which PBAF complexes were also the most enriched.
Finally, ncBAF complexes were most enriched at CTCF sites, particularly CTCF sites co-localized with H3K4me1 ( Supplementary Fig.  2l ). These CTCF co-localized sites comprised a greater portion of all ncBAF peaks relative to cBAF and PBAF peaks. Thus, although the localization and biological roles for mSWI/SNF complexes have been most extensively explored at enhancers [35] [36] [37] [38] , these results imply specialized roles for ncBAF and PBAF complexes at CTCF sites and promoters, respectively, and demonstrate mSWI/SNF complexspecific chromatin localization.
Genome-scale fitness screening reveals cancer-specific dependencies on ncBAF complexes. To determine whether ncBAF
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Fig. 5 | ncBAF is not required for SS18-SSX1-mediated gene expression and primarily regulates fusion-independent sites. a,
Immunoblot for ncBAF components in HA-SS18 and HA-SS18-SSX complex purifications (n = 1 biologically independent experiment). See also Supplementary Fig. 7h . b, Heatmap of significantly downregulated genes (adjusted P < 0.001 and log 2 [fold change] < − 0.59) in shSS18-SSX (7 d postinfection) and dBRD9 (3 d and 6 d postinfection) conditions in SYO-1 cells clustered into four groups according to the k-means. Benjamini-Hochberg adjusted Wald P values; n = 2 biological replicates for each RNA-seq experiment. c, Gene set enrichment analysis (GSEA) of RNA-seq data for shSS18-SSX and dBRD9 (Day 6) conditions in b. Specific pathways and gene sets are indicated. d, Immunoblot of CRL7250 whole cell lysates described in Supplementary Figure 5B (top; n = 1 biologically independent experiment) and heatmap of log 2 [fold change] of gene expression in CRL7250 fibroblast cells treated with DMSO, dBRD9 or dBRD9 followed by lentiviral introduction of V5-SS18 or V5-SS18-SSX (bottom; n = 2 biological replicates for each RNA-seq experiment). The included genes were expressed (> 1 reads per kilobase million (RPKM)) and had a log 2 [fold change] of at least ± 0.59 in at least one of the conditions. Genes were k-means clustered into two groups and samples were clustered hierarchically. See also Supplementary Fig. 7i . e, Heatmap of ChIP-seq read densities of SS18, BRD9 and H3K4me3 over SS18 sites in SYO-1 cells (shScr (control hairpin) and shSSX (targeting SS18-SSX)) conditions clustered into three groups. f, Gene expression of log 2 [fold change] of genes closest to the fusion-dependent sites (n = 595) in shSS18-SSX and dBRD9 conditions. P values were calculated using two tailed t-test; n = 2 independent samples for each ChIP performed. Boxes represent the interquartile range (IQR); horizontal bars, the median; minima and maxima shown extend 1.5 × IQR from the box. g, Chromatin landscape (fusion-dependent, fusion-independent promoter and fusionindependent distal) of BRD9 peak nearest to the 500 most downregulated genes at day 6 of dBRD9 treatment. h, CERES scores of genes demonstrating significant expression changes (adjusted P < 0.001) in SYO-1 cells after 6 d of dBRD9 treatment. P value was calculated using a two tailed t-test. The violin plot represents the kernel density estimation with data quartiles shown as lines and the data median as a dot. 
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NATuRe Cell BIology subunits are uniquely required for the proliferative maintenance of any cancer types, we analysed CRISPR-Cas9-based screens performed across 387 cancer cell lines 26 and performed screens in three new synovial sarcoma cell lines ( Supplementary Fig. 3a ; Achilles 18Q3 dataset, https://cds.team/depmap/#). These screens identified significant, selective sensitivity of both synovial sarcoma and MRT cell lines to perturbations of the ncBAF complex subunits BRD9, GLTSCR1 and SMARCD1 (Fig. 3a) . These dependency profiles were specific to synovial sarcoma and MRT, both of which are sarcomas, and not to other soft-tissue malignancies ( Supplementary  Fig. 3b ). To corroborate these results, we analysed shRNA-based fitness screens from Project DRIVE 29 and again found that synovial sarcoma (n = 5) and MRT (n = 4) cell lines were selectively sensitive to BRD9 suppression ( Fig. 3b and Supplementary Fig. 3c ). We further confirmed that ncBAF dependency was specific to SS18-SSX fusion oncoprotein-positive synovial sarcoma, as a synovial sarcoma histological mimic cell line, SW982 (lacking the SS18-SSX fusion) was insensitive to ncBAF component perturbation (Fig. 3c ).
Both synovial sarcoma and MRT exhibit perturbations to the cBAF core functional module 12 . Synovial sarcoma is uniformly characterized by the t(X;18) chromosomal translocation, which produces the SS18-SSX fusion oncoprotein, a stable and dedicated mSWI/SNF complex subunit that destabilizes SMARCB1 39, 40 , whereas MRT and atypical teratoid/rhabdoid tumour (AT/RT) cell lines are driven by the bi-allelic loss of the SMARCB1 gene (encoding the SMARCB1/BAF47/hSNF5/INI1 subunit [18] [19] [20] ; Supplementary  Fig. 3d ). In synovial sarcoma, the loss of proliferative fitness as a result of ncBAF subunit perturbation was comparable to SS18 perturbation, the driver of disease (Fig. 3a ). Both synovial sarcoma and MRT cell lines exhibited higher sensitivity to the loss of BRD9 than acute myeloid leukaemia cell lines, which have previously been reported to be sensitive to BRD9 knockdown 41, 42 (Fig. 3a and Supplementary Fig. 3c ). We found that acute myeloid leukaemia cell lines exhibited near uniform sensitivity to depletion of a wide range of mSWI/SNF complex subunits, and not uniquely to depletion of ncBAF subunits ( Supplementary Fig. 3e ). In synovial sarcoma and MRT, SMARCB1 (destabilized and deleted in these cancers, respectively) and other cBAF and PBAF subunits, such as SMARCE1, ARID1A and BRD7, did not score as dependencies ( Fig. 3a and Supplementary Fig. 3c ), thus highlighting the selective sensitivity to ncBAF subunit disruption in these cancer types.
To validate these findings, we depleted BRD9, both biologically and chemically, using shRNA and dBRD9 chemical degradation 43 strategies. The suppression of BRD9 in SYO-1 synovial sarcoma cells significantly attenuated their proliferation in comparison to either control shRNA or shRNA directed against SMARCE1, a structurally essential component of cBAF and PBAF complexes that is not a part of ncBAF, thus further confirming the screening results ( Fig. 3d and Supplementary Table 2 ). Synovial sarcoma cells treated with dBRD9 exhibited near complete depletion of BRD9 from whole-cell lysates and proliferative attenuation, approaching that which results from SS18-SSX oncoprotein knockdown (Fig. 3e,f , Supplementary Fig. 3f ,g and Supplementary Table 2 ). Knockdown of GLTSCR1 in SYO-1 cells also attenuated proliferation, providing support for the role of ncBAF complexes in synovial sarcoma cell maintenance ( Supplementary Fig. 3h ). Cell cycle analysis that was performed on cells treated with dBRD9 revealed a decrease in cells in the S phase and an increase in cells in sub-G1, relative to dimethylsulfoxide (DMSO) vehicle control, and annexin V staining demonstrated an increase in apoptotic cells ( Supplementary Fig.  3i,j) . Furthermore, global transcriptional profiling revealed similar effects on gene expression between dBRD9 and shBRD9 treatments, whereas shSMARCE1 resulted in discordant changes and minimal transcriptional effects (Fig. 3g ). Lastly, dBRD9 treatment of SMARCB1-deficient MRT cell lines TTC1240 and G401 resulted in reduced proliferation ( Fig. 3h, Supplementary Fig. 3k and Supplementary Table 2 ), whereas dBRD9 treatment in a SMARCB1intact epithelioid sarcoma cell line ESX did not ( Supplementary Fig.  3l ). As mSWI/SNF complexes in synovial sarcoma and MRT/AT/ RT/epithelioid sarcoma disease settings exhibit the shared feature of cBAF perturbation by SMARCB1 (BAF47) loss or destabilization, these results unmask a selective ncBAF dependency in two aggressive and intractable cBAF-mutant cancer types.
Finally, we compared total degradation of BRD9 (dBRD9 degrader) with BRD9 bromodomain inhibition using BI-7273. Colony formation assays in SYO-1, HSSYII and Aska synovial sarcoma cell lines demonstrated that dBRD9 treatment was substantially and reproducibly more potent than BI-7273 (or treatment with lenalidomide control; Fig. 3i and Supplementary Fig. 3m,n) . Moreover, these treatments in cell lines lacking BAF complex perturbations did not result in the inhibition of colony formation ( Supplementary Fig. 3o-q) . Knockout of BRD9 in HEK-293T cells resulted in destabilized ncBAF complexes ( Supplementary Fig. 3r ), perhaps underlying the increased potency observed with dBRD9 relative to BI-7273. Together, these data suggest that the total loss of BRD9 is more potent than bromodomain inhibition, thus supporting the possibility that other domains of BRD9 may be important for BRD9 subunit function.
CRISPR guide RNA tiling experiments define the required domains on GLTSCR1 and BRD9 ncBAF subunits. We next sought to identify specific regions on BRD9 as well as other ncBAF components that uniquely underlie the synthetic lethality in synovial sarcoma. We performed CRISPR tiling screens with an array of guide RNAs against the exonic sequences of several subunits and their paralogs in the SYO-1 synovial sarcoma cell line ( Fig. 4a and Supplementary Table 2,3) . Guides targeting regions of the disease driver SS18, part of the SS18-SSX fusion, dropped out as expected ( Supplementary Fig. 4a,b) . Consistent with the CRISPR and RNAi screening results above ( Fig. 3) , cBAF/PBAFspecific subunits SMARCB1 and SMARCE1 did not drop out ( Supplementary Fig. 4c,d ) and ncBAF-specific paralogs SMARCD1 and SMARCC1 exhibited more dropout relative to SMARCD2/3 and SMARCC2, respectively, paralogs that do not assemble into ncBAF ( Supplementary Fig. 4e-h) . Interestingly, guides targeting the GLTSCR domain of GLTSCR1 and most of the coding region of BRD9, including the bromodomain and the DUF3512, exhibited significant fitness dropout (Fig. 4b,c) . In contrast, guides targeting the bromodomain and DUF3512 of PBAF-specific BRD7, the paralog of BRD9, did not result in reduced fitness (Fig. 4d ). These data highlight the synthetic lethal specificity for ncBAF components and demonstrate the importance of the GLTSCR and DUF3512 domains of GLTSCR1/1L and BRD9, respectively, in ncBAF function in synovial sarcoma.
To understand the roles of the GLTSCR and DUF3512 domains in ncBAF complexes, we assessed the evolutionary conservation of these regions (Fig. 4e,f) . The most evolutionarily conserved region of the GLTSCR1/1L paralogs is the GLTSCR domain, which suggests that it could possibly serve an important structural role. Indeed, immunoprecipitation followed by immunoblotting of mammalian GLTSCR1 N-and C-terminal truncation mutants demonstrated that this domain is required for interaction with ncBAF complexes and thus serves as an ncBAF-specific binding region ( Fig. 4g and Supplementary Fig. 4i ). In contrast, although the bromodomain and DUF3512 regions are evolutionarily conserved between BRD9 and BRD7 homologs across species (Fig. 4f) , the mammalian BRD9 and BRD7 paralogs incorporate into ncBAF and PBAF complexes, respectively. To determine whether the DUF3512 domain is involved in complex-specific binding of the BRD9 and BRD7 subunits, we performed domain swapping experiments in which we fused the C-terminal DUF-containing region of BRD9 to the N terminus of BRD7 and vice versa (Fig. 4h ). Swapping of BRD9 and Articles NATuRe Cell BIology BRD7 DUF3512 regions resulted in switched complex specification, with BRD9-(BRD7 DUF) binding PBAF complexes and BRD7-(BRD9 DUF) binding ncBAF complexes (Fig. 4h ). Together, these results imply that the BRD9 DUF3512 and the GLTSCR1 GLTSCR domains are ncBAF-complex-binding domains that underlie critical dependencies in synovial sarcoma cell contexts. ncBAF is not required for SS18-SSX fusion-mediated gene expression and primarily regulates retained fusion-independent sites. SS18 is a subunit of both cBAF and ncBAF complexes ( Fig. 1 ) and the SS18-SSX fusion protein is a dedicated and stable subunit in cBAF complexes in synovial sarcoma 39 . To understand the sensitivity of synovial sarcoma cells to ncBAF complex depletion, we investigated whether SS18-SSX incorporates into ncBAF complexes. Complex purifications via haemagglutinin (HA)-tagged wild-type SS18 and SS18-SSX1 revealed that, although ncBAF subunits copurify with SS18-SSX, relative to SMARCA4 they are less robustly captured by purification of SS18-SSX1 than SS18 (Fig. 5a) .
Given that the SS18-SSX1 fusion protein destabilizes SMARCB1, a core subunit in cBAF complexes but not present in ncBAF complexes, we sought to determine whether fusion-containing ncBAF complexes can drive oncogenesis and the hallmark gene expression phenotypes of synovial sarcoma tumours. Thus, we performed RNA-seq on SYO-1 synovial sarcoma cells treated with either an shRNA targeting SS18-SSX (shSSX) or dBRD9. Intriguingly, although treatment with dBRD9 resulted in proliferative attenuation similar to knockdown of the disease-driver SS18-SSX ( Fig. 3) , few genes were concordantly affected by both treatments (Fig. 5b and Supplementary Fig. 5a ). Specifically, although both BRD9 and SS18-SSX perturbations similarly affected cell cycle pathways consistent with proliferative attenuation, we found discordant effects on mesenchymal stem cell differentiation, neural differentiation and bivalent polycomb target genes, gene sets that are hallmarks of the synovial sarcoma-specific oncogenic signature, suggesting different underlying mechanisms (Fig. 5c) 23, 39 .
To determine whether BRD9 (and hence, ncBAF complexes) were required for de novo SS18-SSX-mediated gene activation, we performed RNA-seq in CRL7250 human fibroblasts in which we expressed either wild-type V5-SS18 or V5-SS18-SSX1 fusion with or without 24 h pre-treatment with dBRD9, followed by sustained dBRD9 treatment ( Supplementary Fig. 5b ). Despite full degradation of BRD9 protein, dBRD9 treatment did not attenuate SS18-SSXmediated gene activation and polycomb target genes associated with H3K27me3-mediated repression were equally activated irrespective of dBRD9 treatment ( Fig. 5d and Supplementary Fig. 5c ). These data in the SYO-1 and CRL7250 settings suggest that the function of ncBAF complexes is distinct from that of SS18-SSX-bound cBAF complexes known to oppose polycomb at cancer-specific sites on the genome 23 . In addition, ncBAF is not required for the de novo activation of synovial sarcoma-specific gene signatures driven by the SS18-SSX fusion protein, pointing to a distinct mechanism underlying ncBAF dependency in synovial sarcoma.
We next sought to define the divergent gene regulatory effects between SS18-SSX1 and BRD9 perturbation. In synovial sarcoma, the SS18-SSX fusion protein directs targeting of BAF complexes to a cancer-specific set of sites on chromatin which are crucial for oncogenesis 23 (Fig. 5e ). To assess whether the SS18-SSX fusion hijacks BRD9 to such cancer-specific sites, we performed ChIP-seq for BRD9 before and after SS18-SSX knockdown and found that BRD9 is minimally retargeted by the SS18-SSX fusion to broad-peak fusion-dependent sites (Fig. 5e ). Additionally, fusion-independent sites (sites retained irrespective of SS18-SSX knockdown) are largely marked by H3K4me3 and CTCF (Fig. 5e ), two hallmarks of ncBAF complex targeting (Fig. 2) , whereas fusion-dependent sites are not.
We found that the genes closest to fusion-dependent sites were strongly downregulated by SS18-SSX knockdown 23 , but the expression of these genes did not change with BRD9 degradation ( Fig. 5f and Supplementary Fig. 5d ). Instead, the most downregulated genes following dBRD9 treatment were closest to fusion-independent sites ( Fig. 5g and Supplementary Fig. 5e ). This result is consistent with the lack of requirement for BRD9 in mediating de novo activation of fusion-dependent genes in CRL7250 fibroblasts and the divergent transcriptional effects between shSS18-SSX and dBRD9 treatments in SYO-1 synovial sarcoma cells. Finally, we compared changes in gene expression following dBRD9 treatment with gene dependency scores derived from CRISPR screening and found that genes downregulated by dBRD9 treatment were significantly enriched for sensitivities ( Fig. 5h ). However, dBRD9 treatment in a BAF-intact cancer cell line, such as MOLM-13, did not result in preferential downregulation of genes that are enriched for dependencies ( Supplementary Fig. 5f ). Together, these results support a model in which BRD9/ncBAF complexes are important for the regulation of gene expression at fusion-independent sites. We propose that ncBAF complexes, which preferentially associate with wild-type SS18 and are, in contrast to cBAF complexes, less perturbed by the incorporation of the fusion protein, are critical for maintenance of essential genes at fusion-independent sites in a setting in which SS18-SSX has further targeted cBAF complexes away from these sites.
ncBAF is required for the maintenance of gene expression via retained co-localization with CTCF in SMARCB1-deficient cancers.
In the absence of SMARCB1 in MRT cell lines, residual SMARCA4-marked mSWI/SNF complexes are substantially more localized to promoter-proximal sites and are deficient in enhancer targeting 37, 38 . Previous studies that used Brg1 (Smarca4) conditional knockout in mouse models identified that Smarcb1-deficient cells are still dependent on Smarca4 for survival 44 and these data have been more recently corroborated in large-scale dependency screens in cancer cell lines. Thus, we investigated whether these residual mSWI/SNF complexes in MRT would primarily represent intact ncBAF complexes. We performed ChIP-seq for BRD9 in the MRT cell line TTC1240 and found that BRD9 localizes to a large proportion of SMARCA4 sites (Fig. 6a) . In contrast, ncBAF complexes co-localize with approximately one-third or fewer of all SMARCA4 sites in mSWI/SNF-intact settings, such as MOLM-13 and Jurkat cells, and in MRT TTC1240 cells in which SMARCB1 has been rescued ( Fig. 6b ). Thus, a large percentage of residual mSWI/ SNF complexes that are required for proliferative maintenance in SMARCB1-deficient cell lines represent ncBAF complexes.
BAF complex localization and function at enhancers and superenhancers have been shown to be aberrant in MRT 37, 38 . Thus, we examined BRD9 targeting to MRT-specific super-enhancers, defined by Chun et al. in primary tumours and cell lines compared to hESC lines and fetal brain tissue 45 . The TTC1240 cell line exhibits a strong overlap with these primary tumour-associated MRTspecific enhancers and super-enhancers ( Supplementary Fig. 6a ) and BRD9-marked ncBAF complexes localized to a large number of these MRT-specific super-enhancers, particularly those that encompass a TSS (Fig. 6c ). To investigate the role of BRD9 at these genes in MRT, we treated TTC1240 cells with dBRD9 and performed ChIP-seq and RNA-seq. Treatment with dBRD9 resulted in a significant decrease in SMARCA4 occupancy, particularly at BRD9marked sites genome-wide ( Fig. 6d-f and Supplementary Fig. 6b ). Consistent with overlap at super-enhancers, lost SMARCA4 peaks were highly enriched in H3K27ac relative to peaks that did not change (Fig. 6g ). In addition, many of the downregulated genes had BRD9 occupancy at their promoters and genes that demonstrated significant changes had higher H3K27ac and BRD9 occupancy than active genes without significant changes ( Supplementary Fig. 6c ). Genes that were downregulated by dBRD9 and lost SMARCA4 occupancy were enriched for those genes overexpressed in MRT Articles NATuRe Cell BIology compared to wild-type tissue or defined as regulated by MRTspecific super-enhancers (such as JUND, VGF, ID3, HOXC9 and CREB3L1; Fig. 6h ) 45 and involved in development and differentiation ( Supplementary Fig. 6d ). Finally, the loss of SMARCA4 occupancy was specific to the MRT cell setting, as dBRD9 treatment in MOLM-13, a BAF-intact cell line, did not result in similar loss of SMARCA4 (Fig. 6i ). Similar to synovial sarcoma, these data support a model in which ncBAF complexes, the only mSWI/SNF family complex that is not perturbed by SMARCB1 loss, are critical for the maintenance of gene expression and subsequently the proliferative capacity of MRT cells.
As synovial sarcoma and MRT, which share core cBAF (particularly SMARCB1) perturbation, are dependent on ncBAF complexes that regulate gene expression at retained mSWI/SNF sites, we investigated whether there were any convergent features between these sites in these two distinct disease settings. Importantly, we found that SMARCA4-marked mSWI/SNF complexes in MRTs and synovial sarcoma both converge on a largely promoter-proximal and CTCF co-localized distribution, two hallmarks of ncBAF complex localization (Fig. 2) , relative to SMARCA4 in mSWI/SNF-intact cell types ( Fig. 6j and Supplementary Fig. 6e,f) . In both synovial sarcoma and MRT cell lines, the enrichment of BRD9 at CTCF sites remained unchanged following SS18-SSX knockdown or SMARCB1 reintroduction, respectively, further highlighting that default, hallmark ncBAF complex-specific targeting to promoters and CTCF sites occurs irrespective of BAF complex perturbations ( Fig. 6k and Supplementary Fig. 6g,h) .
These data support a model in which ncBAF complexes maintain gene expression at retained promoter-proximal and CTCF sites when regulatory functions of the core cBAF functional module (containing SMARCB1, SMARCE1 and ARID1A/B) are disrupted (Fig. 6l ). Disruption (either chemical or biological) of ncBAF complex leads to a loss of gene expression maintenance, thus defining the cancer-specific sensitivities of cBAF-perturbed cancers such as synovial sarcoma and MRT (Fig. 6m ).
Discussion
In this study, we generated comprehensive chromatin binding profiles for all three mSWI/SNF family complexes relative to defined genomic features. The occupancy patterns of ncBAF, BAF and PBAF complexes to CTCF sites, active enhancers and active promoters, respectively, may in part underlie complex-specific functions implicated in genome-scale cell fitness screening efforts. These mSWI/ SNF localization studies provide an important platform upon which to identify complex-specific chromatin and histone landscape interaction mechanisms that govern preferential genome-wide targeting profiles. Differences in histone binding affinities, interactions with general or tissue-specific transcription factors, or complex-specific steric constraints for binding specific chromatin features are probably at play, alone and in combination, in directing mSWI/SNF complex targeting.
Importantly, we identified a synthetic lethal relationship in specific cancers with perturbations to the core cBAF functional module, specifically in synovial sarcoma (driven by the SS18-SSX fusion) and SMARCB1-deficient MRT. These cancers are uniquely and specifically dependent on ncBAF complexes for proliferative maintenance, unveiling ncBAF complex subunits as potential targets for therapeutic intervention in these cancers (relative to other cancer types of diverse lineages). Our findings are particularly relevant given the recent development of selective small-molecule inhibitors and chemical degraders targeting BRD9 [41] [42] [43] 46 . Further studies will be needed to carefully define in vivo properties of these compounds. Our identification of domains within ncBAF-specific subunits that underlie these dependencies, such as the GLTSCR domain of GLTSCR1/1L and the DUF3512 of BRD9, further expands therapeutic opportunities.
In characterizing the convergent mechanism of ncBAF dependency in synovial sarcoma and MRT, we unexpectedly found that although ncBAF complexes do incorporate the SS18-SSX fusion that drives synovial sarcoma, perturbation of BRD9 and disruption of SS18-SSX are mechanistically distinct. Non-canonical BAF complexes primarily regulate retained fusion-independent sites, linking to SMARCB1-deficient MRT in which ncBAF complexes comprise a large share of essential residual complexes that similarly maintain gene expression at retained mSWI/SNF sites. The retained sites in both of these disease settings have CTCF co-localization and promoter proximity in common, the two hallmarks of ncBAF complex localization. Thus, this work now provides a complexspecific basis for previously identified dependencies on SMARCA4 (BRG1) in SMARCB1-deficient cancers 44 and highlights the importance of understanding subunit-specific contributions to complex assembly and function when designing strategies to target mSWI/ SNF-perturbed cancers. Our data suggest the possibility that other cBAF-perturbed cancers, such as those with loss of ARID1A/B or SMARCE1 47, 48 , may exhibit similar ncBAF dependencies.
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Methods Cell lines and tissue culture. HEK-293T, G401, TTC1240, ESX, IMR-90, BJ Fibroblast, CRL7250 and NCIH-1437 cells were grown in DMEM (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco) and 1% penicillinstreptomycin (Gibco). ES-2 cells were grown in McCoy's 5A media (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco) and 1% penicillinstreptomycin (Gibco). EoL-1 and MOLM-13 cells were grown in RPMI (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco) and 1% penicillinstreptomycin (Gibco). The human rhabdomyosarcoma (RD) cell line was cultured in DMEM (Gibco) supplemented with 10% FBS. HCT116 cells were grown in McCoy's 5A media (Gibco) supplemented with 10% FBS. Calu-6 cells were grown in Eagle's minimal essential medium (ATCC) supplemented with 10% FBS. SYO-1 cells were grown in DMEM without sodium pyruvate (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco) and 1% penicillin-streptomycin (Gibco). The SYO-1 cell line was a gift from A. Kawai (National Cancer Center Hospital, Japan). The ASKA-SS and HS-SY-II cell lines were obtained from RIKEN 49 . The CRL7250 human fibroblast cell line was a gift from B. Gryder and J. Khan (National Cancer Institute).
Constructs and cloning. Lentiviral shRNA hairpins targeting BRD9 (RHS4430-200302441), SMARCE1 (RHS4430-200219172) and a non-silencing control (RHS4346) were constitutively expressed from the pGIPZ vector (GE Dharmacon) and hairpins targeting GLTSCR1 were inducibly expressed from the pTRIPZ vector (RHS4696; GE Dharmacon).
The shRNA hairpins targeting SS18-SSX (5′ -CAGTCACTGACAGTTAATA AA-3′ ) or a non-targeting scramble control ( 5′ -CCTAAGGTTAAGTCGCCCTC GCTCGAGCGAGGGCGACTTAACCTTAGG-3′ ) were constitutively expressed from the pLKO.1 vector with puromycin selection.
All expression constructs were cloned using In-Fusion HD as per the manufacturer's recommendations. V5-GLTSCR1 and the corresponding N-and C-deletion mutants were synthesized and cloned into a modified pTight vector by GenScript Biotech Corporation. GLTSCR1L (clone 40146333) was cloned with a V5 tag into a modified pTight vector using In-Fusion HD. The HA-tag sequence was included in the primers for human BRD9, BRD7, SMARCD1, DPF2 and GLTSCR1L and cloned into a modified pTight vector under constitutive EF1alpha-driven expression with a blasticidin resistance gene. HA-BRD9(B7C) contains amino acids 1-265 of BRD9 and amino acids 266-651 of BRD7. HA-BRD7(B9C) contains amino acids 1-265 of BRD7 and amino acids 266-597 of BRD9. HA-BRD9(B7C) and HA-BRD7(B9C) were cloned stepwise, with the Nand C-terminal fragments amplified independently, followed by mixing the N-and C-terminal PCR products in equal quantities in a subsequent PCR reaction to fuse the two fragments together into the same modified pTight vector with a puromycin resistance gene. All of the primers used for cloning are listed in Supplementary Table 6 .
Lentiviral production and transduction. The shRNA or gene delivery vectors psPAX2, and pMD2.g were transfected into HEK-293T cells at a ratio of 4:3:1 using PEI (Polysciences, Inc.). The media were filtered through 0.4 µ m filters 72 h post transfection and lentiviral particles were concentrated at 20,000 r.p.m. for 2.5 h at 4 °C using ultracentrifugation with a SW28 rotor. The lentiviral particles were resuspended in 200 µ l PBS and cells were transduced using 1:1000 polybrene (Santa Cruz Biotechnology). Two days post-infection, cells were selected with 2 µ g ml −1 puromycin or 10 µ g ml −1 blasticidin. Proliferation curves. Cells (25,000-40,000 per well) were plated onto 12-well plates, or 50,000-60,000 cells per 10 cm plate, depending on the cell line. Cell counts were performed in biological triplicate using a Vi-CELL XR Cell Counter (Beckman Coulter) on the indicated days.
Colony formation assays. Colony formation assays were performed in a 6-or 12-well format. For each cell line, the appropriate cell seeding conditions were first identified in a 14-day assay format. A titration of the cell numbers of each of the cell lines was performed to identify the best cell-seeding conditions. The compounds were treated continuously for 14 d at the indicated concentrations, with a change of medium every five days. By Day 14, the medium was removed, cells were washed with PBS and stained using 500 ul 0.005% crystal violet (w/v) solution in 25% methanol (v/v) for at least 1 h at room temperature.
Cell cycle analysis. Cell cycle analysis was performed using the Click-iT Plus EdU Flow Cytometry Assay (Invitrogen). Apoptosis assays were performed using the Annexin V-FITC Apoptosis Detection Kit (Sigma) according to the manufacturer's protocol. SYO-1 cells were treated for eight days and the compound was refreshed every five days.
CRISPR domain scanning.
To perform high density sgRNA tiling screens, sgRNA libraries against BAF complex subunits were custom synthesized at Cellecta following Cellecta's recommendations. Negative and positive control sgRNA were included in the library for quality control checks in the screening results. Negative controls consist of 200 sgRNAs that do not target the human genome.
The positive controls are sgRNAs targeting essential genes (CDC16, GTF2B, HSPA5, HSPA9, PAFAH1B1, PCNA, POLR2L, RPL9 and SF3A3). All positive and negative control sgRNAs are listed in Supplementary Table 3 . The procedures for virus production, cell infection and sgRNA screening were previously described in earlier work 26, 50 . For each sgRNA, 50 was added to the sequencing counts and the resulting sums were normalized with the total count. The log 2 of the ratio between the counts (defined as dropout ratio) at Day 24 and Day 1 postinfection was calculated ( Supplementary Table 4 ). For negative control sgRNAs the 2.5th and 97.5th percentiles of the log 2 dropout ratio of all non-targeting sgRNAs were calculated and considered as background (grey box in the graph). Protein domains were obtained from PFAM regions defined for the following UNIPROT identifiers: BRD9, Q9H8M2; BICRA, Q9NZM4; BRD7, Q9NPI1; SMARCA2, P51531; SMARCA4, Q9HBD4; SMARCB1, G5E975; SMARCC1, Q92922; SMARCC2, Q8TAQ2; SMARCD1, Q96GM5; SMARCD2, Q92925; SMARCE1, Q969G3; SS18, Q15532; SSX2, Q16385. Rolling averages were calculated for each nucleotide in the corresponding transcript by selecting a window (150 nucleotides) centred at the corresponding position and calculating the average of the log 2 dropout ratio of the sgRNAs in the window. mSWI/SNF complex purification. Mammalian SWI/SNF complexes were purified as previously described 51 . In this study, complexes were purified from HEK-293T cells stably expressing HA-tagged constructs (as indicated). Cells were scraped from plates and washed with cold PBS. The suspension was centrifuged at 3,000 r.p.m. for 5 min at 4 °C using the Sorvall Legend X1R Centrifuge with the 75003181 rotor, and pellets were resuspended in hypotonic buffer containing 10 mM Tris-HCl pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol (DTT) and 1 mM PMSF and incubated on ice for 5 min. The suspension was centrifuged at 5,000 r.p.m. for 5 min at 4 °C, the pellets were resuspended in five volumes of fresh hypotonic buffer containing a protease inhibitor cocktail and homogenized using glass Dounce homogenizer. The suspension was then layered onto hypotonic buffer sucrose cushion containing 30% sucrose (w/v), centrifuged for 1 h at 5,000 r.p.m. and 4 °C and the cytosol-containing layer was discarded. The nuclear pellets were resuspended in high-salt buffer containing 50 mM Tris-HCl pH 7.5, 300 mM KCl, 1 mM MgCl 2 , 1 mM EDTA, 1 mM, 1% NP40, 1 mM DTT, 1 mM PMSF and a protease inhibitor cocktail. Homogenates were incubated on rotator for 1 h. The homogenates then were centrifuged at 20,000 r.p.m. (30,000 g) for 1 h at 4 °C using an SW32Ti rotor. The chromatin pellets were discarded and the high-salt nuclear extract was filtered through a 0.45 µ m filter and incubated overnight with HA magnetic resin. HA beads were washed four times (1.5 h per wash) in highsalt buffer and eluted with high-salt buffer containing 1 mg ml −1 HA peptide. The eluted proteins were then subjected to density gradient centrifugation or dialysis.
Protein extraction methods. Ammonium sulfate nuclear extraction was performed as reported previously 38 . Pellets were resuspended in IP buffer (300 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA and 1% Triton-X100, supplemented with fresh protease inhibitor, 1 mM DTT and 1 mM PMSF) for subsequent experiments.
For whole cell lysates, cells were washed with PBS and resuspended in approximately five volumes of extraction buffer (20 mM Tris and 1.5% SDS). Chromatin was solubilized through sonication and proteins were quantified using bicinchoninic acid assay (BCA).
Immunoprecipitation. Nuclear extracts were quantified using BCA and 1 mg protein (1 mg ml −1 in IP buffer supplemented with protease inhibitors) was used per immunoprecipitation. Proteins were incubated overnight with 2-5 µ g of antibody or with 25 µ l Pierce Anti-HA Magnetic Beads with rotation at 4 °C. The solution of nuclear extract + antibody was incubated with 30 µ l Protein G Dynabeads (Thermo Fisher) for 2 h at 4 °C with rotation and washed five times with IP buffer. Immunoprecipitated proteins were eluted with sample buffer (2× NuPAGE LDS buffer with 100 mM DTT) and loaded onto 4-12% Bis-Tris NuPAGE Gels (Life Technologies). See the Reporting Summary for the antibodies used in this study.
Glycerol gradient. Linear 10-30% glycerol gradients were prepared in 14 mm × 89 mm polyallomer centrifuge tubes (Beckman Coulter) by overlaying 10% glycerol solution in HEMG buffer on 30% glycerol solution with mixing by a Gradient Master. The nuclear extracts (500-1,000 µ g) were resuspended in 200 μ l HEMG (0% glycerol) and overlaid on the gradient. Purified protein complexes were loaded in their elution buffers. The gradients were centrifuged in an SW41 rotor at 40,000 r.p.m. for 16 h at 4 °C and 0.55 ml fractions were collected for analysis.
Mass spectrometry sample preparation and analysis.
Purified complex elutions (BRD9, BRD7, Mock) or glycerol gradient fractions (DPF2, fractions [13] [14] were concentrated using StrataClean beads, loaded onto 4-12% SDS-PAGE gels, allowed to migrate 2 cm into the gel and stained with colloidal blue (Invitrogen). Stained samples were excised and sent to Taplin Biological Mass Spectrometry Facility at Harvard Medical School for analysis. A heatmap displaying log 2 [number of total peptides + 1] was created using Seaborn.
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Protein SDS-PAGE. Proteins were run on 4-12% Bis-Tris NuPAGE gels (Life Technologies). For Western blotting, the proteins were wet transferred onto PVDF membranes at 300 mA for 2.5 h, blocked for 1 h with 10% milk PBS-T and visualized using LI-COR Odyssey CLx. For silver staining, gels were stained using SilverQuest Silver Staining Kit (Thermo Fisher) according to the manufacturer's protocol.
Chromatin immunoprecipitation. Cells were fixed in 1% formaldehyde (Sigma Aldrich) for 10 min at 37 °C and quenched with 125 mM glycine for 5 min at 37 °C. The cells were then washed with cold PBS and stored at − 80 °C until use. Ten million cells per ChIP were used for EoL-1, MOLM-13 and Jurkat cell lines, and five million cells per ChIP were used for SYO-1 and TTC1240 cell lines. Nuclei were extracted and chromatin was sonicated using the adaptive focused acoustics technology with a Covaris sonicator. Sonicated chromatin was used in overnight immunoprecipitation reactions with the indicated antibodies (see Reporting Summary), followed by capture using Protein G Dynabeads (Thermo Fisher) . For ChIP-seq using spike-in chromatin, 15 ng of spike-in Drosophila chromatin (Active Motif) was added to each sample with 2 µ g spike-in antibody (Active Motif). Captured antibody-chromatin complexes were washed, eluted and treated with RNAse A (Roche) for 30 min at 37 °C and Proteinase K (Life Technologies) for 3 h at 65 °C. ChIP DNA was extracted using SPRI beads (Beckman Coulter Agencourt AMP Xpure), washed and eluted.
RNA-seq sample preparation. RNA was collected from 2 × 10 6 cells per condition, in biological duplicates, using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's protocol.
Library preparation and sequencing. Library preparation and sequencing of ChIP DNA and RNA was performed by the Molecular Biology Core Facilities at the Dana-Farber Cancer Institute (75 bp single end on Illuminia Nextseq 500).
ChIP-Seq data alignment. The ChIP-seq data were aligned using Bowtie2, version 2.1.0 52 to map reads to the hg19 human reference genome, using the parameter -k 1.
For spike-in normalization, Drosophila DNA was aligned to the dm3 genome using Bowtie2 version 2.1.0 with the parameter -k 1. Duplicated reads were removed using samtools rmdup with the -b option (SAMtools v1.3.1). As per the manufacturer's instructions, the normalization ratios were calculated using the ratio of the total number of non-redundant mapped reads in each sample to the sample with the fewest non-redunant mapped reads.
ChIP-Seq data analysis. Data processing. MACS2 53 version 2.1.0 was used to call peaks against input with a cutoff of q = 0.001. In EoL-1, MOLM-13 and TTC1240 cells, narrow peaks were called for all SWI/SNF antibodies and CTCF, whereas broad peaks were used for all histone marks. In SYO-1 cells, broad peaks were called for all antibodies. Peaks that fell in ENCODE blacklisted regions or were mapped to unmappable chromosomes (not chr1-22, X or Y) were removed. Quality control metrics are available in Supplementary Table 5 . All of the downstream analysis was performed on bam files with duplicates removed using the samtools rmdup command with the -b option. ChIP-seq tracks were generated using the bedGraphToBigWig script downloaded from UCSC. Bedgraph files were generated with MACS2 using the -B -SPMR options. For the TTC1240 SMARCA4 tracks shown, the bedGraph file values were multiplied by the spike-in normalization ratios calculated as described above.
Overlaps for ChIP Venn diagrams were created using the ChIPPeakAnno 54 v3.10.1 bioconductor package, the peak files were read using the toGRanges() command and values were determined using the getVennCounts() function with maxgap = 0. Data was visualized using matplotlib. The number of overlapping peaks displayed in pie charts, bar charts and heatmaps was determined using the pybedtools 55 intersect function. Proportions were calculated by dividing the number of overlapping peaks by the number of total peaks.
Read counts across peak sets of interest were calculated by calling the Rsubread 56 v1.26.1 bioconductor package function featureCounts() on duplicate removed bam files. These values were divided by the total number of mapped reads divided by one million, giving a normalized value of RPM for each interval in the input bed.
Peak distance from TSS elements was determined using BEDtools v2.26.0 closest function with the hg19 ref Flat TSS annotation.
Determination of super-enhancers was performed using the default settings in ROSE 57, 58 ; the TTC1240 H3K27ac ChIP-seq file and TTC1240 H3K27ac peak file were used as inputs. MRT-specific super-enhancers were downloaded from Chun et al 45 and merged using bedtools merge, as many of their published enhancers abutted one another.
Data analysis and visualization. Metagene plots and heatmaps were generated created using HTSeq 59 v0.9.1. To account for the 200 bp average fragment length selected for in sonication, the fragment length was extended by 200 bp from the edge of each genomic interval. Total read counts for each interval were normalized to reads RPM. For each antibody, the resulting matrix has a width of the number of base pairs in the window (in this study primarily 5,000) and a height of the number of peaks in the indicated set. Strandedness of the interval was not considered, except for the TSS metagene plot in Supplementary Fig. 2g . Metagene plots show the average RPM at each position. Heatmaps were visualized using python. Heatmaps were ordered by the maximum value in each matrix row of the indicated antibody. Heatmaps were coloured such that the midpoint of the colour spectrum is equivalent to the median of the set of maximum values in each row. For heatmaps where multiple peak sets are shown, these colour values were calculated for each antibody across both sets together. For the spike-in normalized heatmap, all heatmap data was calculated as described but then multiplied by the normalization factor, described above, before plotting.
In the heatmap of EoL-1 histone marks and CTCF sites in Supplementary Fig.  2i , the HTSEQ procedure described above was carried over peaks that had been split into 100 bins and 2,500 bp on either side of the peak. The resulting matrix was k-means clustered to four clusters. This was carried out over the merged set of all EoL-1 mSWI/SNF peaks.
The SYO-1 differential heatmap (Fig. 5e ) was ordered by the ratio of the row means for BRD9 in the + /-shSSX conditions. Any interval that had an increase in mean BRD9 ChIP occupancy of at least 25% following shSSX treatment was considered gained. Any interval that had at least 25% decrease in mean BRD9 ChIP occupancy following shSSX treatment was considered lost. Intervals that did not change more than 25% in either direction were considered retained.
Differential occupancy of SMARCA4 in TTC1240 following dBRD9 treatment was determined using the DiffBind v2.4.8 bioconductor package (https:// bioconductor.org/packages/release/bioc/html/DiffBind.html), with all default settings. Peak files and duplicate-removed bam files were provided for each SMARCA4 sample in each condition, along with the bam files corresponding to the input in each condition. The package functions count(), contrast(), analyze() and report() were used in sequence.
Gene ontology of genes near lost SMARCA4 sites in TTC1240 ( Supplementary  Fig. 6d ) was performed using the Genomic Regions Enrichment of Annotations Tool (GREAT) 60 .
Motif analysis. A fasta sequence for a region of 250 bp on either side of the centre of each peak was generated using the bedtools getfasta function. Motif analysis on these sequences was done using the MEME-ChIP suite 61 .
In Fig. 2d , the motif with the highest CentriMo log-adjusted P value in the indicated transcription factor family was selected for each antibody. These logadjusted P values were used to make a heatmap using the Seaborns clustermap function, clustered by correlation.
Enrichment plots for the motifs are the average number of the CentriMo site counts for each antibody in the window around the indicated motif split into bins of 10 bp.
RNA-Seq data analysis. Data processing. RNA-seq data reads were mapped using default parameters to hg19 using STAR 62 version 2.5.2a.
RPKM values were calculated using GFOLD version 1.1.4 63 . Unless otherwise noted, log 2 [fold change] and Bonferroni-corrected P values were generated using DESEQ2 v1.16.1, with reads mapped using RSUBREAD 56 v1.26.1. Genes were considered significantly altered if they had an adjusted P < 0.001 and a log 2 [fold change] of at least 0.59 (approximately 50% change). All RNA-seq experiments were performed with biological replicates. Quality control metrics are available in Supplementary Table 5 .
RNA BigWig files were generated using the bamCoverage command from deepTools release 2.4 64 with all default settings.
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Data collection
Raw Illumina output was converted to fastq format using Illumina Bcl2fastq v2.18.
Data analysis
All open source packages that were used to process and analyze data in this study are detailed below in the "Software" section of ChIPseq, and include MACS2 version 2.1.0, bedGraphToBigWig from UCSC, ChIPPeakAnno v3.10.1, pybedtools, Rsubread v1.26.1, BEDtools v2.26.0, ROSE, HTSeq v0.9.1, the DiffBind v2.4.8, MEME ChIP suite, and Genomic Regions Enrichment of Annotations Tool (GREAT). Packages used to analyze RNA-seq data include STAR 2.5.2a, GFOLD version 1.1.4, DESEQ2 v1.16.1, Rsubread v1.26.1, deepTools release 2.4, Gene Set Enrichment Analysis (GSEA), and Metascape. Any scripts or code written by the authors are available upon request from the corresponding author.
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